The study lacks functional validations of downstream PI3K/AKT regulators (e.g., GSK-3β, mTOR, FOXO proteins) and rescue experiments using AKT activators to further delineate the mechanistic link between PI3K/AKT inhibition and ferroptosis in cancer therapy. The gene discussed is GSK3B; the disease is cancer.